AI Engines For more Details: Perplexity Kagi Labs You
Blood Glucose Control: Gliquidone helps to lower blood sugar levels by stimulating the release of insulin from the pancreas. It is effective in controlling hyperglycemia (high blood sugar) in patients with type 2 diabetes mellitus.
Insulin Secretagogue: As a sulfonylurea, gliquidone acts as an insulin secretagogue, meaning it promotes the release of insulin from the beta cells of the pancreas. This mechanism helps to lower blood glucose levels by increasing insulin availability.
Hypoglycemia: One of the main side effects of gliquidone is hypoglycemia, or low blood sugar levels. This can occur if the dose of gliquidone is too high relative to the individual's insulin needs or if meals are skipped or delayed.
Weight Gain: Some individuals may experience weight gain while taking gliquidone. This can be due to the medication's effect of increasing insulin levels, which can promote fat storage.
Gastrointestinal Effects: Gliquidone may cause gastrointestinal side effects such as nausea, vomiting, diarrhea, or abdominal discomfort in some patients. These effects are usually mild and transient.
Skin Reactions: Rarely, gliquidone may cause skin reactions such as rash or itching. If these symptoms occur, patients should consult their healthcare provider.
Liver Function: Gliquidone can affect liver function, although significant liver toxicity is rare. Liver function tests may be monitored periodically in patients taking gliquidone, especially those with pre-existing liver conditions.
Allergic Reactions: Some individuals may experience allergic reactions to gliquidone, although these are rare. Symptoms of an allergic reaction may include rash, itching, swelling, dizziness, or difficulty breathing. Immediate medical attention is necessary if an allergic reaction occurs.
Drug Interactions: Gliquidone may interact with other medications, including other antidiabetic drugs, leading to changes in blood sugar levels or an increased risk of hypoglycemia or other adverse effects. It's important for patients to inform their healthcare providers about all medications they are taking.
Cardiovascular Effects: While gliquidone itself does not directly affect the cardiovascular system, maintaining good blood sugar control with medications like gliquidone can reduce the risk of long-term cardiovascular complications associated with diabetes, such as heart disease and stroke.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 1.4 | 0.3 | 3.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.5 | 0.7 | 1.14 |
| Allergies | 2 | 1.9 | 0.05 |
| Allergy to milk products | 0.8 | 1 | -0.25 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.7 | 1.7 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.3 | 0.67 |
| Ankylosing spondylitis | 2.1 | 0.6 | 2.5 |
| Anorexia Nervosa | 1.5 | 1.3 | 0.15 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 1.9 | 1 | 0.9 |
| Atherosclerosis | 1.1 | 0.2 | 4.5 |
| Atrial fibrillation | 1.8 | 1.6 | 0.13 |
| Autism | 3.4 | 3.3 | 0.03 |
| Autoimmune Disease | 0.6 | 0.5 | 0.2 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 1.2 | 0.3 | 3 |
| Brain Trauma | 0.6 | 0.9 | -0.5 |
| Breast Cancer | 0.3 | 0.3 | 0 |
| Cancer (General) | 0.4 | -0.4 | |
| Carcinoma | 1.6 | 1.3 | 0.23 |
| Celiac Disease | 0.8 | 1.3 | -0.63 |
| Cerebral Palsy | 1.1 | 0.6 | 0.83 |
| Chronic Fatigue Syndrome | 1.5 | 1.8 | -0.2 |
| Chronic Kidney Disease | 1.4 | 1.4 | |
| Chronic Lyme | 0.6 | 0.3 | 1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.3 | 2 |
| Chronic Urticaria (Hives) | 0.5 | 0.8 | -0.6 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.6 | 0.17 |
| Cognitive Function | 1.6 | 0.8 | 1 |
| Colorectal Cancer | 3.2 | 0.8 | 3 |
| Constipation | 0.6 | 0.6 | |
| Coronary artery disease | 0.6 | 0.5 | 0.2 |
| COVID-19 | 2.4 | 3.3 | -0.38 |
| Crohn's Disease | 2.6 | 1.5 | 0.73 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | -0.7 | |
| deep vein thrombosis | 0.5 | 0.9 | -0.8 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 2.8 | 1.8 | 0.56 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.5 | 1.7 | -2.4 |
| Endometriosis | 1.3 | 0.3 | 3.33 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.2 | 1 | 0.2 |
| erectile dysfunction | 0.8 | 0.3 | 1.67 |
| Fibromyalgia | 1.3 | 1.4 | -0.08 |
| Functional constipation / chronic idiopathic constipation | 2 | 2.4 | -0.2 |
| gallstone disease (gsd) | 1.1 | 0.3 | 2.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.3 | -0.5 |
| Generalized anxiety disorder | 0.6 | 1.1 | -0.83 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.5 | 1 |
| Graves' disease | 1.3 | 1.2 | 0.08 |
| Gulf War Syndrome | 0.5 | 0.7 | -0.4 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.1 | 0.6 | 0.83 |
| Heart Failure | 2.1 | 0.6 | 2.5 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.4 | 0.6 | -0.5 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.6 | 1 | -0.67 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 1.6 | 1.7 | -0.06 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.4 | 0.9 | 0.56 |
| IgA nephropathy (IgAN) | 1.3 | 1.4 | -0.08 |
| Inflammatory Bowel Disease | 3.7 | 3 | 0.23 |
| Insomnia | 1.2 | 0.9 | 0.33 |
| Intelligence | 0.5 | 0.6 | -0.2 |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 1.9 | 1.8 | 0.06 |
| ischemic stroke | 1.6 | 0.3 | 4.33 |
| Liver Cirrhosis | 2.6 | 1.4 | 0.86 |
| Long COVID | 2 | 1.7 | 0.18 |
| Lung Cancer | 0.1 | 0.3 | -2 |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.5 | 0.6 | -0.2 |
| ME/CFS without IBS | 0.5 | 1.2 | -1.4 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 0.4 | |
| Metabolic Syndrome | 2.1 | 2.1 | 0 |
| Mood Disorders | 3 | 1.8 | 0.67 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 2.3 | 3.4 | -0.48 |
| Multiple system atrophy (MSA) | 0.6 | -0.6 | |
| myasthenia gravis | 0.3 | 0.2 | 0.5 |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0.3 | 0.4 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2 | 1 | 1 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 3.1 | 2.7 | 0.15 |
| obsessive-compulsive disorder | 1.9 | 1.5 | 0.27 |
| Osteoarthritis | 1.1 | 1.2 | -0.09 |
| Osteoporosis | 0.8 | 0.6 | 0.33 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 3 | 3.1 | -0.03 |
| Polycystic ovary syndrome | 2.7 | 1.5 | 0.8 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.3 | 0.5 | -0.67 |
| Primary sclerosing cholangitis | 1.2 | 1.5 | -0.25 |
| Psoriasis | 1.3 | 2 | -0.54 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.3 | 1 | 1.3 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 2.1 | 1.5 | 0.4 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 1.4 | 1.1 | 0.27 |
| Sleep Apnea | 0.6 | 0.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1.2 | 1 | 0.2 |
| Systemic Lupus Erythematosus | 1.4 | 1.2 | 0.17 |
| Tic Disorder | 0.6 | 0.9 | -0.5 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 1.3 | 1.5 | -0.15 |
| Type 2 Diabetes | 1.9 | 2.3 | -0.21 |
| Ulcerative colitis | 2.2 | 3.2 | -0.45 |
| Unhealthy Ageing | 1.4 | 0.7 | 1 |
| Vitiligo | 1.8 | 0.9 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
